Poliovirus vaccine inactivated
Highest phase reached
Phase 3
Drug type
Vaccine component
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Vaccine component
- Drug name
- Poliovirus vaccine inactivated
- opvero oral poliomyelitis vaccine
- oral poliomyelitis vaccine
- Oral Poliomyelitis Vaccine
- Oral poliomyelitis vaccine (OPV)
- poliomyelitis vaccine
- Poliomyelitis vaccine
- poliovirus vaccine inactivated
- Poliovirus vaccine inactivated
- ChEMBL ID
- CHEMBL2107962
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -vir-
- Condition
- Virus Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000763
- Subject identifier
- D014777
- Condition
- Malaria
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001068
- Subject identifier
- D008288
- Condition
- Rotavirus Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002622
- Subject identifier
- D012400
- Condition
- Meningococcal Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004249
- Subject identifier
- D008589
- Condition
- Poliomyelitis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007450
- Subject identifier
- D011051
- Condition
- Postpoliomyelitis Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007454
- Subject identifier
- D016262
- Condition
- Gastroenteritis
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001463
- Subject identifier
- D005759
- Condition identifier
- EFO_0000763
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002622
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007450
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007454
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001463
- Highest recorded phase
- 3
Reported adverse events
- Event
- vaccination complication
- Reports
- 1
- Reporting signal score
- 8.81946
- NCT00258843
- NCT00348387
- NCT00604058
- NCT01048190
- NCT01056705
- NCT01510366
- NCT01708720
- NCT01709071
- NCT01813604
- NCT02111135
- NCT02231632
- NCT02291263
- NCT02347423
- NCT02434770
- NCT02985320
- NCT03016949
- NCT03025750
- NCT03032419
- NCT03092791
- NCT03169725
- NCT03239496
- NCT03526978
- NCT03671616
- NCT04232943
- NCT04264598
And 13 more, listed on the interactive page.
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (37)
- A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants
- A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
- A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children
- A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults
- Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
- Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine
- Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)
- Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)
- Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom
- Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants
- Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV
- Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine
- Inactivated Poliomyelitis Vaccine Made From Sabin Strain
- Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults
- Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT
- Live Enterovirus Vaccine and Type 1 Diabetes
- Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .
- Phase III Study on Rotavirus Vaccine to Evaluate Lot-to-lot Consistency and Interference With Routine UIP Immunization
In development for (7)
- Gastroenteritis Phase 3
- Malaria Phase 1
- Meningococcal infection Phase 3
- Poliomyelitis Phase 3
- Postpoliomyelitis syndrome Phase 2
- Rotavirus infection Phase 3
- Viral infectious disease Phase 3